Mirae Asset Global Investments Co. Ltd. Acquires 5,913 Shares of Repligen Co. (NASDAQ:RGEN)

Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 46.5% in the fourth quarter, Holdings Channel.com reports. The fund owned 18,629 shares of the biotechnology company’s stock after purchasing an additional 5,913 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Repligen were worth $2,679,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in RGEN. UMB Bank n.a. raised its position in Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares in the last quarter. Resources Management Corp CT ADV bought a new position in shares of Repligen during the 3rd quarter worth approximately $37,000. Quarry LP boosted its stake in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 239 shares in the last quarter. Finally, nVerses Capital LLC acquired a new stake in Repligen in the 3rd quarter valued at $45,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. Canaccord Genuity Group started coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Finally, HC Wainwright decreased their price target on Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $184.73.

Repligen Trading Down 3.6 %

Shares of RGEN opened at $156.05 on Monday. The stock’s fifty day simple moving average is $155.37 and its 200-day simple moving average is $148.93. The firm has a market capitalization of $8.74 billion, a PE ratio of -421.75, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $211.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same period in the prior year, the company posted $0.23 EPS. The company’s revenue was up 9.7% compared to the same quarter last year. As a group, research analysts predict that Repligen Co. will post 1.54 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.